Expanding the phenotype spectrum of β-mannosidosis
Angela M. Martin Rios, Karolina M. StępieńiD, Liliane GibbsiD, Katherine Hall, Patricia HalliD, Gisele Bentz PinoiD, Raymond WangiD, Nishitha R. PillaiiD, Troy C. LundiD, Paul J. OrchardiD, Virginia E. KimonisiD
Abstract
PurposeTo expand the spectrum of clinical and biochemical phenotypes, and brain imaging features of individuals with {beta}-mannosidosis, a rare lysosomal storage disease. MethodsWe describe the clinical features of six patients with {beta}-mannosidosis, their findings on brain magnetic resonance imaging (MRI), and the changes over time in two of them. We also review previously reported patients, analyze the variants in MANBA, the first symptom and spectrum of symptoms, and the ages of onset and of diagnosis of the disease. ResultsForty-four patients have been reported to date, including our patients. The mean age of diagnosis is 12.8 years, and the age of onset of symptoms is 2.4 years. Hearing loss is the most frequently reported initial symptom and intellectual disability is the most frequent symptom overall. Erythromelalgia, nystagmus, macrocephaly, and obsessive-compulsive-like behavior are newly described features associated with {beta}-mannosidosis. 40% of the patients have abnormal brain imaging. Brain MRI showed hypomyelination in one patient and abnormal white matter changes in another patient. Twenty-nine pathogenic variants in MANBA have been reported among the 44 patients; 60.6% of patients have private variants, and 39.4% have the recurrent variant c.2158-2A>G. A new oligosaccharide structure: Neu-Man2-GlcNac2, was found in the urine of two affected patients. ConclusionDue to disease heterogeneity, establishing a genotype-phenotype correlation remains challenging in {beta}-mannosidosis. A spectrum of brain MRI abnormalities are described as manifestations of this condition: delayed myelination, hypomyelination, and abnormal white matter signals. Additional studies are needed to delineate the pathophysiology of this condition.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- FWCI
- 3.22
- Field percentile
- top 8%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- GM1 Gangliosidosis Type II: Results of a 10-Year Prospective Study
Precilla D’Souza, Cristan Farmer, … Cynthia J. Tifft·Genetics in MedicinePeer-reviewed·Apr 16, 2024
- Myeloid-derived β-hexosaminidase is essential for neuronal health and lysosome function: implications for Sandhoff disease
Kate Inman Tsourmas, Claire Ann Butler, … Kim N. Green·bioRxiv·Oct 21, 2024
- Secondary deficiency of neuraminidase 1 contributes to CNS pathology in neurological mucopolysaccharidoses via hypersialylation of brain glycoproteins
TianMeng Xu, Rachel Heon‐Roberts, … Alexey V. Pshezhetsky·Journal of Clinical InvestigationPeer-reviewed·Jun 17, 2025
- The schizophrenia risk locus in SLC39A8 alters brain metal transport and plasma glycosylation
R. G. Mealer, B. J. Jenkins, … J. W. Smoller·bioRxiv·Jan 14, 2020
- Contribution of brain intrinsic branched-chain amino acid metabolismin a novel mouse model of maple syrup urine disease
Amanda Kuhs, Laura Ohl, … Rebecca C. Ahrens‐Nicklas·Journal of Inherited Metabolic DiseasePeer-reviewed·Feb 4, 2025
- Early defects in lysosomal storage diseases disrupt excitatory synaptic transmission
Camila De Britto Pará De Aragão, Luigi Bruno, … Alexey V. Pshezhetsky·bioRxiv·Jul 6, 2020